Member Info for FreeTheCaterham7

I also won’t be bumping Multy’s threads by replying to them, at least not on the original thread.

"I read that as we're likely to see a paring back of exploration and development."
I agree.

Learnings
1. Eason Chen is a muppet and was completely out of his depth.

2. Following production numbers is all very well, but ultimately the only metric that matters is profitability. Oh, and cashflow.

3. Don't get sucked in by +ve noises fro m the company, or posters on here who are permanently uber bullish

4. Its not comms that matter, ibut performance.

I don't Bradbury is the problem.
The problem was the previous FD.

The comments on here tend to give a false impression of how significant the news is

Looks more like a deep dive into old data to me.

Or he's just talking about SNG001, the clinical trials didn't have the outcome we wanted, and it won't be available to patients in 2022.

At first sight this comment is the most positive thing to come out of SNG for a while. I have some questions that better informed posters can no doubt help me with...
A new treatment? Does that mean not SNG001?
What trials are they on that are current?
When he says "available" does he mean in trials? Surely not as a commercial drug?

Mildly encouraging

Yes but what Kevin says is correct.

"No treatments are being investigated"

Dunk. Why?

"Wouldnt be surprised if Poly ( together with another party) is thebuyer
Their best chance to make a good return"

How would that work?

I think Mr Costs might have been taking the mickey.

"under embargo due to containing commercially sensitive information"

I hope so, but I doubt it
Prove me wrong RM

RM one of 164 speakers.
Probably nothing new to say.
I think this will be a bit of a non-event. I do not expect it to impact the share price either way. We need platform trial for that.

Charts schmarts

Rambler still off most investors’ radar
It has messed up too often for people who don’t know it to believe unquantified promises.

It will to get some attention when it publishes financials showing a profit.

@1111112
There's no robust evidence of Hydroxychloroquine curing Covid19.

Well said Doc.Daneeka